NEXAVAR for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 141 adverse event reports in the FDA FAERS database where NEXAVAR was used for Hepatocellular carcinoma.
Most Reported Side Effects for NEXAVAR
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 46 | 12.6% | 14 | 18 |
| Hepatocellular carcinoma | 42 | 11.5% | 33 | 12 |
| Palmar-plantar erythrodysaesthesia syndrome | 36 | 9.9% | 16 | 11 |
| Hepatic cancer | 27 | 7.4% | 9 | 8 |
| Decreased appetite | 24 | 6.6% | 9 | 12 |
| Hypertension | 22 | 6.0% | 8 | 8 |
| Fatigue | 20 | 5.5% | 5 | 7 |
| Renal cancer | 20 | 5.5% | 1 | 0 |
| Rash | 19 | 5.2% | 6 | 6 |
| Abdominal pain | 18 | 4.9% | 4 | 10 |
| Nausea | 18 | 4.9% | 5 | 12 |
| Pain in extremity | 18 | 4.9% | 3 | 6 |
| Ascites | 17 | 4.7% | 10 | 12 |
| Death | 17 | 4.7% | 16 | 4 |
| Hepatic encephalopathy | 17 | 4.7% | 9 | 13 |
Other Indications for NEXAVAR
Hepatic cancer (103)
Renal cancer (29)
Renal cell carcinoma (16)
Thyroid cancer (10)
Metastases to lung (6)
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)